Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
Related Experiment Video
Updated: Jun 12, 2026

Development and Validation of a Quantitative PCR Method for Equid Herpesvirus-2 Diagnostics in Respiratory Fluids
Published on: March 17, 2016
Erik J Dasbach1, Nathalie Largeron, Elamin H Elbasha
1Health Economic Statistics, Biostatistics and Research Decision Sciences, Merck Research Laboratories, UG1C-60, PO Box 1000, North Wales, PA 19454-1099, USA. erik_dasbach@merck.com.
Abstract:
To assess the epidemiological and economic impact of alternative quadrivalent human papillomavirus (HPV) vaccine strategies in Norway, we adapted a previously published dynamic transmission model. Vaccination of girls and women aged 12-24 years reduced the incidence of HPV 6/11/16/18-related genital warts, cervical intraepithelial neoplasia and cervical cancer by 94, 92 and 92% by year 100, respectively. The cost-effectiveness ratio for this strategy when compared with vaccinating girls before the age of 12 years only was 63,294 Norwegian kroner (euro8272) per QALY gained. Based on this model and assumptions, implementation of a quadrivalent HPV vaccine national program in Norway could reduce the incidence of cervical cancer, cervical intraepithelial neoplasia and genital warts at a cost-effectiveness ratio within the range accepted as cost effective.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Pharmacodynamic Models: Additive and Proportional Drug Effect Model
Pharmacodynamic Models: Linear Concentration–Effect Model
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Pharmacodynamic Models: Overview
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.